HLB Therapeutics Q1 2026: Operating Loss Widens, Debt Ratio Improves
-
Consolidated revenue KRW 13.0bn, down 13.3% YoY (from KRW 15.0bn)
-
Operating loss of KRW 3.2bn, widening from KRW 1.6bn loss in prior year
-
Net loss of KRW 4.4bn, similar to KRW 4.5bn in prior year
-
Debt ratio improved to 30.31% (from 31.51% at year-end)
-
Capitalized R&D costs of KRW 91.0bn (for DED and NK)
-
Cold chain vaccine distribution accounts for 76.6% of revenue, core business
-
Electronics business spin-off completed (subsidiary Koains)
-
Pending litigation for vaccine bid-rigging (KRW 202mn)
-
5% bonus share issuance (approx. KRW 2.1bn) in Q1
KOSDAQ Filing Information
-
Filing: Quarterly Report (2026.03)
-
Company: HLB Therapeutics (115450)
-
Submission: HLB Therapeutics
-
Receipt: 05-15-2026